Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.).

No abstract

SummaryBackground Dose intensifi cation with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diff use large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefi t from dose intensifi cation persists in the presence of rituximab (R-CHOP) in all age groups.

No abstract

Our meta-analysis of individual patient data suggests no differences in efficacy between cisplatin and carboplatin in the first-line treatment of SCLC, but there are differences in the toxicity profile.

HDT significantly improves PFS and OS. There is no clear evidence of benefit through purging.

No abstract

The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.